Inflammation, Poverty Have Synergistic Effect on Mortality
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Jan. 17, 2024 -- There is a potential synergistic effect for inflammation and living in poverty with increased mortality risk for adults, according to a study published online Jan. 16 in Frontiers in Medicine.
Arch G. Mainous III, Ph.D., from the University of Florida in Gainesville, and colleagues examined whether there is a synergistic effect of the presence of inflammation and poverty on the 15-year risk for all-cause, heart disease, and cancer mortality among U.S. adults. The authors evaluated data from the National Health and Nutrition Examination Survey (1999 to 2002) with linked records to the National Death Index through Dec. 31, 2019. The 15-year mortality risk was assessed among adults aged 40 years and older.
The researchers found that the risk for 15-year adjusted, all-cause mortality was increased for individuals with elevated C-reactive protein (CRP) at 1.0 mg/dL and poverty compared with those with low CRP and above poverty (hazard ratio, 2.45). The mortality risk was essentially the same for those with one at-risk characteristic (hazard ratios, 1.58 and 1.59 for low inflammation/poverty and inflammation/above poverty, respectively); these risks were substantially lower than those seen for adults with both inflammation and poverty. The 15-year heart disease mortality risk was elevated by 127 percent and 15-year cancer mortality was elevated by 196 percent for individuals with both elevated inflammation and living in poverty.
"Inflammation and poverty are well known risk factors for mortality, but when both exist simultaneously and CRP is >1.0 mg/dL, they have the potential to increase mortality more than one would expect from an additive effect," the authors write. "This is particularly concerning in socially disadvantaged patients who are already a medically vulnerable population."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-01-18 02:15
Read more
- Shorla Oncology Announces U.S. FDA Expanded Approval of Jylamvo (methotrexate), an Oncology and Autoimmune Drug for Pediatric Indications
- Mixed Link Seen for Gestational Exposure to Flame-Retardant Chemicals and Childhood Obesity
- Genetic Testing Rate Lower for Blacks With Inherited Retinal Diseases
- Native Hawaiian and Pacific Islander Adults Have High CVD Mortality
- Poll Finds Public Fears Over RSV Have Eased, Although It Remains a Threat
- Blood Test Might Spot Women in Labor at Risk for Preeclampsia
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions